ClinicalTrials.gg
CompletedNCT07501052Updated Jun 8, 2026

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

A Phase 2 interventional study of SCD411 0.05mL (2mg) in Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion and Diabetic Macular Edema, sponsored by Sam Chun Dang Pharm. Co. Ltd.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Sam Chun Dang Pharm. Co. Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
49th of 66
33 · median 55
Started
2026
with 3 others
Phase 2
7 of 66
none open now
Registered
63rd of 66
by date

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 49th largest by enrollment, is one of 4 that started in 2026, is one of 7 in phase 2, and was the 63rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR)

03

Conditions studied

  • Neovascular (Wet) Age-Related Macular Degeneration
  • Retinal Vein Occlusion
  • Diabetic Macular Edema
  • Diabetic Retinopathy

Keywords

  • Usability Study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Providers must meet all of the following criteria to be eligible for the study:

  • Be an ophthalmologist with a retinal specialty or with IVT training
  • Be board-certified by the American Board of Ophthalmology
  • Be licensed to practice medicine in the state where patients are seen
  • Be able to conduct physical examinations, including but not limited to ophthalmic examinations, on patients prior to and after injection
  • Have access to appropriate tools and equipment for pre- and post-injection examinations and monitoring

Patients must meet all of the following criteria to be eligible for the study:

  • Be ≥18 years of age
  • Have a confirmed diagnosis of neovascular AMD, DME, RVO, or DR (uni- or bilateral)
  • Have a study eye deemed to be indicated for treatment with SCD411 IVT therapy, as indicated on the US-Eylea label
  • Be capable of understanding the written and signed informed consent (patient or legally authorized representative)
  • Be willing and able to attend all scheduled study visits and comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria will not be eligible for the study:

  • Have active intraocular or periocular infection or active intraocular inflammation (grade: trace or above) in the study eye at Baseline, which is of clinical significance according to the investigator's (HCP's) judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or -associated uveitis, or endophthalmitis
  • Have uncontrolled IOP >25 millimeters of mercury (mmHg) in the study eye at Screening or Day 1 (uncontrolled defined as IOP >25 mmHg despite IOP-lowering therapy)
  • Be deemed legally blind in one or both eyes (Best-corrected visual acuity [BCVA] of 20/200 or worse)
  • Have a history of or any current indication of excessive bleeding or recurrent hemorrhages, including any prior excessive intraocular (including subconjunctival) bleeding or hemorrhages after IVT injection or intraocular procedures in either eye
  • Have current systemic infectious disease
  • Have a history of any medical, ocular, or non-ocular conditions that, in the opinion of the HCP, may interfere with the injection procedure or pose a safety concern
  • Have a history of stroke or or myocardial infarction
  • Have uncontrolled hypertension (defined as a systolic value ≥160 mmHg or diastolic value ≥100 mmHg at Screening, even if taking antihypertensive medication)
  • Have received treatment with anti-VEGF (vascular endothelial growth factor) IVT injection in the study eye within 28 days prior to Screening
  • Have any use of intraocular in the study eye within 3 months prior to Screening
  • Have received any systemic anti-VEGF within the 6 months prior to Screening
  • Have received any invasive intraocular surgery, prior long-acting therapeutic agent, or implantation of an ocular drug-release device (approved or ) in the study eye within the past 3 months prior to Screening
  • Be a woman who is pregnant or breastfeeding or planning to become pregnant while enrolled in the study and for 3 months after SCD411 administration
  • Be a sexually active patient or their partner, be of (i.e., neither surgically sterile nor ), and refuse to use adequate (e.g., true abstinence, sterilization, injectable hormonal contraception, birth control pills, contraceptive implants, or other highly effective methods) while in the study and for 3 months after SCD411 administration. Male patients must agree not to donate sperm during the study and for 3 months following a dose of SCD411
  • Have an allergy or to SCD411, to any of the of SCD411 or aflibercept, or to other study-related procedures/medications (e.g., anesthesia, antiseptic)
  • Have previously been enrolled in this study
  • Have participated in any interventional clinical study within 3 months prior to screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    SCD411

    Drug: SCD411 0.05mL (2mg)

Interventions

  • Single intravitreal therapy (IVT) injection using a prefilled syringe (PFS)

    Also known as: aflibercept

06

What researchers measure

Primary outcomes

  1. Percentage of successful task completions for product use tasks (from opening the carton to disposal of the used PFS and needle)

    Successful completion is defined as achieving the correct results without a usage error. A usage error is defined as an action or lack of action by the user of the PFS that leads to a result that is not intended by the manufacturer

    Time frame: Baseline [Day 1]

  2. Percentage of successful completions of safety-related critical tasks

    Critical tasks are tasks that, if not performed correctly (or at all), would or could cause serious harm to the patient or user

    Time frame: Baseline [Day 1]

  3. Percentage of successful completions of essential tasks

    Essential tasks are tasks that are not critical but are required to complete the use process for effective use of SCD411

    Time frame: Baseline [Day 1]

Secondary outcomes

  1. Number of ocular adverse events (AEs) in the study eye

    Time frame: Baseline through follow up visit - approximately 7 (+2) days post injection

  2. Number of serious adverse events (SAEs) in the study eye

    Time frame: Baseline through follow up visit - approximately 7 (+2) days post injection

  3. Number of non-ocular SAEs

    Time frame: Baseline through follow up visit - approximately 7 (+2) days post injection

07

Study locations

4 sites
  • East Florida Eye Institute
    Stuart, Florida 34994, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • University Retina & Macula Associates, P.C
    Lemont, Illinois 60439, United States
  • Retina Vitreous Surgeons of Central New York, PC
    Liverpool, New York 13088, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in May 2026, 0 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 0 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartActual
May 13, 2026
Primary completionActual
May 27, 2026
CompletionActual
Jun 1, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07501052
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
May 13, 2026
Primary completion
May 27, 2026
Completion
Jun 1, 2026
Last update
Jun 8, 2026

Study contacts

Byung Jhip Ha
study director · Sam Chun Dang Pharm. Co. Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion